1. Samotij D, Nedoszytko B, Bartosińska J, et al. Pathogenesis of psoriasis in the “omic” era. Part I. Epidemiology, clinical manifestation, immunological and neuroendocrine disturbances. Adv Dermatol Allergol 2020; 37: 135-53.
2.
Hsu D, Fung M, Chen HL. Role of skin and gut microbiota in the pathogenesis of psoriasis, an inflammatory skin disease. Med Microecol 2020; 4 (Supl 1): 100016.
3.
Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of chronic plaque psoriasis and its intersection with cardiometabolic comorbidities. Front Pharmacol 2020; 11: 117.
4.
Dascǎlu R, Bărbulescu A, Stoica L, et al. Review: a contemporary, multifaced insight into psoriasis pathogenesis. J Personal Med 2024; 14: 535.
5.
Rønholt K, Nielsen AL, Johansen C, et al. IL-37 expression is downregulated in lesional psoriasis skin. Immunohorizons 2020; 4: 754-61.
6.
Wulamujiang A, Ozkanlı S, Coskunpinar E, et al. Lowered IL‐37 gene expression and elevated IL‐37‐producing tissue‐resident immune cells in psoriasis lesional biopsies. Pathol Int 2023; 73: 490-6.
7.
Watanabe A, Kamata M, Shimizu T, et al. Serum levels of angiogenesis‐related factors in patients with psoriasis. J Dermatol 2022; 50: 222-8.
8.
Conti P, Pregliasco F, Bellomo R, et al. Mast cell cytokines IL-1, IL-33, and IL-36 mediate skin inflammation in psoriasis: a novel therapeutic approach with the anti-inflammatory cytokines IL-37, IL-38, and IL-1Ra. Int J Mol Sci 2021; 22: 8076.
9.
Suzuki T, Hirakawa S, Shimauchi T, et al. VEGF-A promotes IL-17A-producing γδ T cell accumulation in mouse skin and serves as a chemotactic factor for plasmacytoid dendritic cells. J Dermatol Sci 2014; 74: 116-24.
10.
Chen Y, Tai Z, Zhu C, et al. Vascular endothelial growth factor A VEGFA inhibition: an effective treatment strategy for psoriasis. Int J Mol Sci 2024; 25: 59.
11.
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci 2019; 20: 1475.
12.
Patil D, Sumathy TK, Shyamprasad AL. Relevance of serum vascular endothelial growth factor (VEGF) and serum interleukin-10 in the severity of psoriasis in psoriasis in South Indian patients. A case-control study. Turk J Dermatol 2023; 17: 6-10.
13.
Lao J, Xie Z, Qin Q, et al. Serum LL‐37and inflammatory cytokines levels in psoriasis. Immun Inflamm Dis 2024; 11: e802.
14.
Dombrowski Y, Schauber J. Cathelicidin LL‐37: a defense molecule with a potential role in psoriasis pathogenesis. Exp Dermatol 2012; 21: 327‐30.
15.
Nestle FO Kaplan DH, Bake J. Psoriasis. N Engl J Med 2009; 361: 496-509.
16.
Słucznowska-Głabowska S, Jaworska W, Staniszewska M, et al. Plasma levels of interleukins 36α, 36β, and 37 in patients with psoriasis and their correlation with disease activity parameters. J Clin Med 2022; 11: 5254.
17.
Yuan Y, Qiu J, Lin ZT, et al. Identification of novel autoantibodies associated with psoriatic arthritis. Arthritis Rheum 2019; 71: 941‐51.
18.
Tsuji G, Yamamura K, Kawamura K, et al. Regulatory mechanism of the IL-33–IL-37 axis via aryl hydrocarbon receptor in atopic dermatitis and psoriasis. Int J Mol Sci 2023; 24: 14633.
19.
Rønholt K, Nielsen AL, Johansen C, et al. IL-37 expression is downregulated in lesional psoriasis skin. Immunohorizons 2020; 4: 754-61.
20.
Luengas-Martinez A, Paus R, Young H. A novel personalized treatment approach for psoriasis: anti-VEGF-A therapy. Br J Dermatol 2023; 186: 782-91.
21.
Mohta A, Mohta A, Ghiya B. Assessing the association between psoriasis and cardiovascular ischemia: an investigation of vascular endothelial growth factor, cutaneous angiogenesis, and arterial stiffness. Indian Dermatol Online J 2023; 14: 653-7.
22.
Sobolev V, Muminova M, Zhukova O, et al. HGF, HNRPD, and sFLT1 interfere with the induction of VEGF in patients with severe psoriasis. Curr Mol Med 2024; 30: 477-89.
23.
Du Y, Jiang S, Cheng L, Liu J. JAK/STAT and VEGF/PAK1 signaling as emerging targets for topical treatment of psoriasis: a pilot study. Int J Clin Exp Pathol 2020; 13: 3111-9.
Copyright: © Polish Society of Allergology This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivatives 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
